树突状细胞（DC）是先天免疫和适应性免疫交叉点的关键参与者，使其成为抗癌疫苗开发的理想候选者。基于 DC 的免疫疗法通常涉及分离患者来源的 DC，用肿瘤相关抗原 (TAA) 或肿瘤特异性抗原 (TSA) 脉冲它们，并利用成熟混合物来确保它们的有效激活。然后将这些成熟的 DC 回输以引发肿瘤特异性 T 细胞反应。虽然这种方法已证明能够产生有效的免疫反应，但由于免疫抑制的肿瘤微环境，其临床疗效受到限制。最近的努力集中在增强基于 DC 的疫苗的免疫原性，特别是通过与 T 细胞靶向免疫疗法的联合疗法。本试验观察总结了基于 DC 的癌症治疗的最新进展，包括新的临床前和临床策略的开发，并讨论了基于 DC 的疫苗在不断发展的免疫肿瘤学领域的未来潜力。© 2024 作者。经泰勒许可出版

Dendritic cells (DCs) are critical players at the intersection of innate and adaptive immunity, making them ideal candidates for anticancer vaccine development. DC-based immunotherapies typically involve isolating patient-derived DCs, pulsing them with tumor-associated antigens (TAAs) or tumor-specific antigens (TSAs), and utilizing maturation cocktails to ensure their effective activation. These matured DCs are then reinfused to elicit tumor-specific T-cell responses. While this approach has demonstrated the ability to generate potent immune responses, its clinical efficacy has been limited due to the immunosuppressive tumor microenvironment. Recent efforts have focused on enhancing the immunogenicity of DC-based vaccines, particularly through combination therapies with T cell-targeting immunotherapies. This Trial Watch summarizes recent advances in DC-based cancer treatments, including the development of new preclinical and clinical strategies, and discusses the future potential of DC-based vaccines in the evolving landscape of immuno-oncology.© 2024 The Author(s). Published with license by Taylor & Francis Group, LLC.